SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-309383
Filing Date
2021-10-27
Accepted
2021-10-27 16:35:57
Documents
15
Period of Report
2021-10-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d239776d8k.htm   iXBRL 8-K 34331
2 EX-10.1 d239776dex101.htm EX-10.1 37560
3 EX-10.2 d239776dex102.htm EX-10.2 15081
4 EX-99.1 d239776dex991.htm EX-99.1 10885
  Complete submission text file 0001193125-21-309383.txt   251115

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20211022.xsd EX-101.SCH 2914
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20211022_lab.xml EX-101.LAB 18889
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20211022_pre.xml EX-101.PRE 11875
8 EXTRACTED XBRL INSTANCE DOCUMENT d239776d8k_htm.xml XML 3471
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39425 | Film No.: 211353488
SIC: 2836 Biological Products, (No Diagnostic Substances)